Verici Dx plc (LON:VRCI – Get Free Report) shares were up 19% during mid-day trading on Wednesday. The stock traded as high as GBX 0.25 and last traded at GBX 0.25. Approximately 3,421,732 shares traded hands during mid-day trading, an increase of 116% from the average session volume of 1,587,362 shares. The stock had previously closed at GBX 0.21.
Verici Dx Price Performance
The company has a quick ratio of 8.49, a current ratio of 3.94 and a debt-to-equity ratio of 3.03. The company has a market cap of £5.15 million, a price-to-earnings ratio of -0.25 and a beta of 1.22. The stock’s 50-day simple moving average is GBX 0.23 and its 200 day simple moving average is GBX 0.36.
Verici Dx Company Profile
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
See Also
- Five stocks we like better than Verici Dx
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
